Oncotarget

Clinical Research Papers:

Clinical predictive factors of pathologic complete response in locally advanced rectal cancer

Francesca De Felice _, Luciano Izzo, Daniela Musio, Anna Lisa Magnante, Nadia Bulzonetti, Federico Pugliese, Paolo Izzo, Pierfrancesco Di Cello, Pietro Lucchetti, Sara Izzo and Vincenzo Tombolini

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:33374-33380. https://doi.org/10.18632/oncotarget.8133

Metrics: PDF 1384 views  |   HTML 1671 views  |   ?  


Abstract

Francesca De Felice1, Luciano Izzo2, Daniela Musio1, Anna Lisa Magnante1, Nadia Bulzonetti1, Federico Pugliese2, Paolo Izzo2, Pierfrancesco Di Cello2, Pietro Lucchetti2, Sara Izzo2, Vincenzo Tombolini1,3

1Department of Radiotherapy, Policlinico Umberto I “Sapienza” University of Rome, Rome, Italy

2Department of Surgery “Pietro Valdoni”, Policlinico Umberto I “Sapienza” University of Rome, Rome, Italy

3Spencer-Lorillard Foundation, Rome, Italy

Correspondence to:

Francesca De Felice, email: fradefelice@hotmail.it

Keywords: rectal cancer, concomitant treatment, radiotherapy, neoadjuvant, athologic complete response

Received: January 30, 2016    Accepted: March 02, 2016    Published: March 16, 2016

ABSTRACT

Background: Predictive factors of pathologic complete response (pCR) after neoadjuvant chemoradiotherapy (nCRT) in locally advanced rectal cancer (LARC) are still not identified. The purpose of this study was to define them.

Materials and Methods: Data from consecutive LARC patients treated between January 2008 and June 2014 at our Institution were included in the analysis. All patients were treated with a long course of nCRT. Demographics, initial diagnosis and tumor extension details, as well as treatment modalities characteristics were included in the univariate and logistic regression analysis.

Results: In total 99 patients received nCRT, of whom 23 patients (23.2%) achieved pCR. Patients with and without pCR were similar in term of age, sex, comobidities, BMI and tumor characteristics. Multivariate logistic regression indicated that pre-treatment tumor size ≤ 5 cm was a significant predictor for pCR (p = 0.035), whereas clinical N stage only showed a positive trend (p = 0.084).

Conclusions: Tumor size at diagnosis could be used to predict pCR, and thus to individualize therapy in LARC patients management. Validation in other studies is needed.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 8133